Latest Breaking News On - Samarendra mohanty - Page 1 : comparemela.com

Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress

/PRNewswire/ Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today.

United statesUniversity of south floridaFort lauderdalePeter kaiserChristine kaySamuel baroneSamarendra mohantyPrnewswire nanoscope therapeutics incRetina world congressNanoscope therapeutics incClinical trials at vitreoretinal associatesFort lauderdale marriott harbor beach hotelTherapeutics incMulti characteristic opsinPoster numberWednesday posters

Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

/PRNewswire/ Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today.

United statesSubrata batabyalNajam sharifVinitb mahajanSamarendra mohantySamuel baroneNanoscope therapeutics incPrnewswire nanoscope therapeutics incProfessor of ophthalmology at stanford universitySeattle convention centerClinical developmentGlobal researchTherapeutics incMulti characteristic opsinNanoscope therapeuticsConvention center

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events Data from the Phase 2b RESTORE trial.

United statesDavid boyerPsulagna bhattacharyaArshadm khananiSamarendra mohantyReno school of medicineRetina researchRetina service at wills eye hospitalDrug administrationNanoscope therapeutics incNational eyeScientific meeting of the association for researchClinical research at sierra eye associatesUniversity of nevadaBiologics license applicationAnnual scientific meeting

Nanoscope Therapeutics Announces Positive Top-Line Results From Randomized Controlled Trial Of MCO-010 For Retinitis Pigmentosa

Nanoscope Therapeutics Announces Positive Top-Line Results From Randomized Controlled Trial Of MCO-010 For Retinitis Pigmentosa
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesSamarendra mohantyDavid boyerArshadm khananiPsulagna bhattacharyaNational eyeClinical research at sierra eye associatesUniversity of nevadaDrug administrationRetina service at wills eye hospitalScientific meeting of the association for researchNanoscope therapeutics incRetina researchReno school of medicineBiologics license applicationAnnual scientific meeting

Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference

/PRNewswire/ Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced.

United statesJared stephensSamarendra mohantyNanoscope therapeutics incMiami convention centerStrategy business developmentPrnewswire nanoscope therapeutics incBusiness developmentTherapeutics incChief scientific officerVice presidentAnnual advanced therapies week conferenceGene therapyChief scientificGene therapy highlightMulti characteristic opsin